Key Insider Jack C. Bendheim Sells $8.0M in Shares Over Two Months
PAHC has more than doubled off its 52-week low of $17.17.
Summary
A major insider, Jack C. Bendheim, disclosed selling approximately $8.0 million worth of Phibro Animal Health Corporation shares over the last two months, signaling a reduction in his direct stake.
Key Events · Ownership and Investor Activity · PAHC
-
Significant Insider Sales
Jack C. Bendheim, a key insider and Class A Manager of BFI Co., LLC, reported selling 149,429 shares of Class A Common Stock.
-
Substantial Proceeds
The sales generated approximately $8.0 million in proceeds for the reporting persons.
-
Ongoing Stake
Despite the sales, Bendheim and BFI Co., LLC still beneficially own 19,591,914 shares, representing 48.3% of the total Class A Common Stock (assuming conversion of Class B shares).
-
Multi-Month Activity
The transactions occurred between February 20, 2026, and April 23, 2026, as detailed in Exhibit 3.
Analysis · PAHC · Life Sciences
Jack C. Bendheim, a significant insider and Class A Manager of BFI Co., LLC, has reported substantial sales of Phibro Animal Health Corporation stock. The sales, totaling approximately $8.0 million across 149,429 shares, occurred over the past two months. While these are not 10b5-1 pre-planned sales, they represent a notable reduction in direct holdings by a key individual with significant control over the company. Investors should monitor future insider activity for further insights into management's sentiment.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PAHC was trading at $54.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $17.17 to $60.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.